Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Holding GPCR?
Track your performance easily
GPCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$26.61 - $62.74
Previous Close$31
Volume483.55K
Average Volume (3M)780.84K
Market Cap
$1.77B
Enterprise Value$863.97M
Total Cash (Recent Filing)$915.29M
Total Debt (Recent Filing)$4.38M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Mar 27, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding57,260,673
10 Day Avg. Volume824,896
30 Day Avg. Volume780,838
Standard Deviation0.26
R-Squared0.24
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)2.01
Price to Sales (P/S)91.53
Price to Cash Flow (P/CF)-22.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.08
Forecast
1Y Price Target
$89.11Price Target Upside183.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Structure Therapeutics, Inc. Sponsored ADR News
PremiumStock Analysis & Ideas
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Structure Therapeutics Advances Obesity Treatment Candidate
PremiumCompany Announcements
Structure Therapeutics Reports Strong Q3 2024 Results
PremiumPre-Earnings
Is GPCR a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Market PositionThe company's oral GLP-1 is differentiated in a market with high unmet need for more convenient and cheaper options.
Product DevelopmentStructure’s focus on oral obesity medicines, particularly the lead asset GSBR-1290, is the future of long-term obesity therapy, allowing physicians to easily titrate doses, plan for intermittent dosing especially in cases like pregnancy, and allow optimization of treatment algorithm, once the required weight loss has been achieved.
Strategic VisionThe portfolio-based approach which includes oral nutrient sensitive hormonal (NuSH) drugs allows the company to establish a futuristic fully sustainable obesity focused company that might allow plethora of potential combination therapies.
Bears Say
Health RisksIncreased heart rate is a noted side effect in patients treated with incretins, which could raise concerns about the medication's safety profile.
Product Side EffectsA considerable percentage of patients experience adverse side effects such as nausea, vomiting, and constipation, raising concerns about the product's overall tolerability.
Stock Market SentimentShort interest is high, with 21.4% of the stock's float being sold short, indicating significant bearish sentiment among investors.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $26.61 and its highest was $62.74 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Currently, no data Available
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 27, 2025 which is in 99 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 13, 2024. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.182 by -$0.018.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -$0.23.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,260,674 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.182. Following the earnings report the stock price went up 3.629%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Among the largest hedge funds holding Structure Therapeutics, Inc. Sponsored ADR’s share is Driehaus Capital Management LLC. It holds Structure Therapeutics, Inc. Sponsored ADR’s shares valued at 111M.
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.11 (183.07% Upside)
$89.11 (183.07% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 42.4%
Last 30 Days ▲ 42.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.59%
12-Months-Change
Fundamentals
Return on Equity
-20.36%
Trailing 12-Months
Asset Growth
331.31%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc is a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
---
GPCR Stock 12 Month Forecast
Average Price Target
$89.11
▲(183.07% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
+9.21%
reiterated a buy rating 14 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of +9.21% per trade.
---